Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30

ASCO 2009 - Bladder Cancer Session Highlights
ASCO 2009 - Randomized Trial of p53 Targeted Adjuvant Therapy for Patients with Organ-Confined Node-Negative Urothelial Bladder Cancer - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - Studies have suggested a prognostic role for p53 in patients with urothelial carcinoma (UC) of the bladder.
Login to read more...

ASCO 2009 - A Multicenter Phase II Study of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Chemotherapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU-0475 - Session Highlights
Wednesday, 03 June 2009
ORLANDO, FL, USA (UroToday.com) - This study investigated the addition of bevacizumab to the standard regimen of cisplatin/gemcitabine as first-line therapy for patients with metastatic urothelial carcinoma (UC).
Login to read more...

ASCO 2009 - A Phase II Study of Sunitinib on a Continuous Dosing Schedule in Patients with Relapsed or Refractory Urothelial Carcinoma - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Sunitinib has demonstrated activity as a second-line agent for patients with advanced urothelial carcinoma (UC) when administered on a 4 week on, 2 week off schedule.
Login to read more...

ASCO 2009 - Vascular Thromboembolic Events in Patients with Advanced Urothelial Cancer Treated with Carboplatin/Gemcitabine Alone or in Combination with Bevacizumab - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Cisplatin-based chemotherapy is the first-line agent for metastatic urothelial carcinoma (UC).
Login to read more...

ASCO 2009 - Adjuvant Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Little evidence exists regarding the use of adjuvant chemotherapy following radical nephroureterectomy for the management of patients with upper tract urothelial carcinoma (UTUC).
Login to read more...

ASCO 2009 - Prognostic Risk Group Classification for Patients with Platinum-Refractory Metastatic Urothelial Cancer Treated with Second-Line Chemotherapy - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - Second-line chemotherapy agents for patients with platinum-refractory metastatic urothelial cancer (UC) are associated with low response rated and short progression-free and overall survival rates.
Login to read more...

ASCO 2009 - Ethnic Differences in Bladder Cancer Survival - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - As with many other cancers, racial disparities in bladder cancer have demonstrated poorer outcomes for African Americans.
Login to read more...

ASCO 2009 - A Single Institution Experience with Induction and Maintenance Intravesical Docetaxel in the Management of Non-Muscle-Invasive Bladder Cancer Refractory to BCG Therapy - Session Highlights
Tuesday, 02 June 2009
ORLANDO, FL, USA (UroToday.com) - An initial Phase I trial of intravesical docetaxel treatment for patients with non-muscle-invasive bladder cancer demonstrated impressive initial response rates, but disappointing durability.
Login to read more...

 
<< Start < Prev 1 Next > End >>
Results 1 - 8 of 8
back

UroToday, 1802 Fifth Street, Berkeley CA 94710
510.540.0930 (fax), info@urotoday.com
ISSN 1939-4810
About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use


Privacy Policy | © 2009 UroToday ® All Rights Reserved

Member's Section

Login

Sign Up

Quick Search


Advanced Search

Meet the Expert


All Experts


Featured Conference

Working with Industry

Case Studies
Sponsorship Opportunities

Conference Reports
Sponsored By